期刊文献+

油酰乙醇胺对氧化性低密度脂蛋白诱发的动脉粥样硬化反应的作用

Effect of Oleoylethanolamide on Atherosclerosis Response Induced by ox-LDL
下载PDF
导出
摘要 探讨油酰乙醇胺(OEA)对氧化性低密度脂蛋白(ox-LDL)诱导的人脐静脉内皮细胞(HUVEC)坏死的影响及对ox-LDL诱导的小鼠巨噬细胞(RAW264.7)内炎性因子表达变化的影响.实验用ox-LDL诱导HUVEC坏死和RAW264.7细胞内炎性反应;显微镜下观察细胞形态,并收集细胞进行Annexin V/PI-FITC染色,流式细胞分析细胞坏死率;采用实时定量PCR(real-ti me PCR)和酶联免疫吸附剂检测(ELISA)测定mRNA和蛋白水平表达的变化.结果显示:OEA能缓解ox-LDL诱导的HUVEC的坏死,并能呈浓度依赖性的上调HUVEC内过氧化物酶体增殖激活受体α(PPAR-α)和SIRT-1的表达;OEA降低ox-LDL诱导的RAW264.7肿瘤坏死因子α(TNF-α)和CRP mRNA表达的升高,及降低ox-LDL诱导的促动脉粥样硬化因子M-CSF mRNA表达的升高,同时升高ox-LDL诱导SIRT-1表达的降低.实验结果表明,OEA通过激活PPAR-α和抗炎通路对动脉粥样硬化有一定的作用. The effect of OEA on ox-LDL induced atherosclerosis response was investigated.HUVEC and RAW 264.7 cells treated with ox-LDL were used to induce necrosis and inflammation,respectively.Cell necrosis was detected by AnnexinⅤ/PI-FTIC staining and flow cytometer.The expression level of mRNA and protein were detected by quantitative real-time PCR and ELISA.Data showed that,in HUVEC cells,OEA inhibits necrosis induced by ox-LDL through activation of PPAR-α and SIRT-1 expression.In RAW 264.7 cells,OEA decreased the expression levels of inflammatory cytokines,including TNF-α and CRP,and pro-atherosclerosis factor,M-CSF.Furthermore,OEA treatment reversed the expression of SIRT-1,which was suppressed by ox-LDL.The data suggests that OEA played a certain role on atherosclerosis through activation of PPAR-α and anti-inflammatory pathway.
机构地区 厦门大学医学院
出处 《厦门大学学报(自然科学版)》 CAS CSCD 北大核心 2011年第1期127-131,共5页 Journal of Xiamen University:Natural Science
  • 相关文献

参考文献14

  • 1Glass C K, Witatum J L. Atherosclerosis: the road ahead [J]. Cell, 2001,104 (4): 503-516.
  • 2Goldstein J L,Brown M S. The low-density lipoprotein pathway and its relation to atherosclerosis[J]. Annu Rev Biochem, 1977,46 : 897-930.
  • 3Steinberg D. Lipoproteins and atherosclerosis:a look back and a look ahead[J]. Arteriosclerosis, 1983,3 (4) : 283- 301.
  • 4Goldstein J L, Ho Y K, Basu S K, et al. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition[J]. Proc NatI Acad Sci USA, 1979,76 (1) :333-337.
  • 5Boyd H C, Gown A M, Wolfbauer G, et al. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit [J ]. Am J Pathol, 1989,135(5) : 815-825.
  • 6Quinn M T, Parthasarathy S,Fong L G, et al. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis[J]. Proc Natl Acad Sci USA, 1987, 84: 2995-2998.
  • 7Steinberg D, Parthasarathy S, Carew T E, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity[J]. New England Journal of Medicine, 1989,320(14) : 915-924.
  • 8Hessler J R, Robertson A L Jr, Chisolm G M. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture [J]. Atherosclerosis, 1979,32 (3): 213-229.
  • 9Lefebvre P, Chinetti G, Fruchart J C, et al. Sorting out the roles of PPAR-a in energy metabolism and vascular homeostasis[J]. J Clin Invest, 2006,116 (3) : 571-580.
  • 10Patsouris D, Muller M, Kersten S, et al. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance[J]. Curr Opin Investig Drugs, 2004,5 (10) : 1045-1050.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部